Although many kinds of therapies are applied in the clinic, drug-resistance is a major and
unavoidable problem. Another disturbing statistic is the limited number of drug targets, which …

Receptor tyrosine kinase signalling pathways have been successfully targeted to inhibit
proliferation and angiogenesis for cancer therapy. However, kinase deregulation has been …

Over the past two decades there has been a great deal of interest in the development of
inhibitors of the cyclin-dependent kinases (CDKs). This attention initially stemmed from …

Protease-targeted chimeras (PROTACs) are a new technology that is receiving much
attention in the treatment of diseases. The mechanism is to inhibit protein function by …

Cyclin-dependent kinases (CDKs) are proteins pivotal to a wide range of cellular functions,
most importantly cell division and transcription, and their dysregulations have been …

Proteolysis targeting chimaeras (PROTACs) is a cutting edge and rapidly growing technique
for new drug discovery and development. Currently, the largest challenge in the molecular …

Cyclin-dependent kinase 9 (CDK9), a member of the cyclin-dependent protein kinase (CDK)
family, is involved in transcriptional elongation of several target genes. CDK9 is ubiquitously …

Simple Summary CDK9, in combination with Cyclin T1, is one of the major regulators of RNA
Polymerase II mediated productive transcription of critical genes in any cell. The activity of …

Inhibition of cyclin-dependent kinases (CDKs) has become an effective therapeutic strategy
for treating various diseases, especially cancer. Over almost three decades, although great …

A CDK9 inhibitor having short target engagement would enable a reduction of Mcl-1 activity,
resulting in apoptosis in cancer cells dependent on Mcl-1 for survival. We report the …